AXL and nonpapillary renal cell carcinoma: 2014). A selective small molecule Axl kinase inhibitor (BGB324) is currently in Phase II clinical trials for acute myeloid leukemia, melanoma and non‐small cell lung cancer. AXL inhibition in experimental ccRCC models is beneficial indicating a new therapeutic option (Yu et al. 2015).